Transgenic News and Research

RSS

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Researchers identified a human monoclonal antibody (mAb), 87G7, with in vitro neutralizing activity against several SARS-CoV-2 VOCs, including Alpha, Beta, Gamma, Delta, and Omicron.

28 Apr 2022

Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious

Researchers compared the efficiency of monovalent and bivalent mRNA vaccines against SARS-CoV-2.

22 Apr 2022

Study evaluates the ocular tropism and the possible ocular transmission of SARS-CoV-2 in animal models

Researchers demonstrated ocular tropism of SARS-CoV-2 through neuronal invasion in transgenic mice with hACE2 expression.

20 Apr 2022

Effects of COVID-19 treatment best with combination therapy

There is a steadily growing arsenal of drugs for COVID-19. Researchers from Charité – Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC) and Freie Universität (FU) Berlin have studied the mechanisms of action of antiviral and anti-inflammatory drugs.

15 Apr 2022

Insights into the pathogenesis of the previous and circulating SARS-CoV-2 variants in mice

A recent article presented the diverse pathogenesis of SARS-CoV-2 variants of concern in a humanized mouse model.

7 Apr 2022

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

A new study presented the rapid profiling of a SARS-CoV-2 Delta-Omicron recombinant sequence from Europe.

6 Apr 2022

Mosaic-8 RBD-nanoparticles show promise as a vaccine candidate for SARS-CoV-2 and potential sarbecoviruses spillovers

Researchers designed nanoparticles representing RBDs of the S protein of animal sarbecoviruses and SARS-CoV-2 to evaluate their potential as a pan-sarbecovirus vaccine candidate.

31 Mar 2022

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

Researchers discuss the use of the isothiocyanate sulforaphane for the treatment of both SARS-CoV-2 and HCoV-OC43 infections.

30 Mar 2022

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Tuberculosis infection protects mice against COVID-19

To study if prior Mtb infection affects the response to CoV2 infection, K18-hACE2 (ACE2) and C57BL/6 (B6) mice were infected with Mtb, and post thirty days, were exposed to CoV2.

27 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Researchers investigated how monoclonal antibodies, S309 and AZD7442, reduced lung infection in mice infected with the SARS-CoV-2 new variant of concern Omicron's BA.1, BA.1.1, and BA.2 sublineages.

23 Mar 2022

Lettuce could protect astronauts from bone density loss in microgravity

Astronauts might one day grow and eat genetically modified plants to ward off disease associated with long spaceflights. Researchers at the University of California, Davis College of Engineering have developed a transgenic, or genetically modified, lettuce producing a drug to protect against bone density loss in microgravity.

22 Mar 2022

Transgenic News and Research

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious

Study evaluates the ocular tropism and the possible ocular transmission of SARS-CoV-2 in animal models

Effects of COVID-19 treatment best with combination therapy

Insights into the pathogenesis of the previous and circulating SARS-CoV-2 variants in mice

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

Mosaic-8 RBD-nanoparticles show promise as a vaccine candidate for SARS-CoV-2 and potential sarbecoviruses spillovers

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Tuberculosis infection protects mice against COVID-19

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Lettuce could protect astronauts from bone density loss in microgravity

Study evaluates COVID-19 vaccination with recombinant accessory protein-deficient SARS-CoV-2

Researchers receive grant to find answers to taste loss in COVID patients

Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News